Baxter International (BAX) 10-Q 30 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 25, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'BAX	'
Entity Registrant Name	'BAXTER INTERNATIONAL INC	'
Entity Central Index Key	'0000010456	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	541,673,382

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (USD $)	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$4,264	$3,669	$8,215	$7,117
Cost of sales	2,223	1,730	4,213	3,422
Gross margin	2,041	1,939	4,002	3,695
Marketing and administrative expenses	998	838	1,918	1,633
Research and development expenses	325	273	638	519
Net interest expense	42	17	85	42
Other expense (income), net	15	68	-9	65
Income before income taxes	661	743	1,370	1,436
Income tax expense	141	153	294	294
Net income	$520	$590	$1,076	$1,142
Net income per common share	'	'	'	'
Basic	$0.96	$1.09	$1.98	$2.10
Diluted	$0.95	$1.07	$1.96	$2.07
Weighted-average number of common shares outstanding	'	'	'	'
Basic	542	543	542	543
Diluted	548	549	548	550
Cash dividends declared per common share	$0.52	$0.49	$1.01	$0.94

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net income	$520	$590	$1,076	$1,142
Other comprehensive (loss) income, net of tax:	'	'	'	'
Currency translation adjustments, net of tax (benefit) of ($12) and ($11) for the three months ended June 30, 2014 and 2013, respectively, and ($8) and ($4) for the six months ended June 30, 2014 and 2013, respectively	-213	-30	-207	-54
Pension and other employee benefits, net of tax expense of $14 and $20 for the three months ended June 30, 2014 and 2013, respectively, and $23 and $44 for the six months ended June 30, 2014 and 2013, respectively	28	32	51	77
Hedging activities, net of tax expense (benefit) of $4 and ($8) for the three months ended June 30, 2014 and 2013, respectively, and ($2) and $11 for the six months ended June 30, 2014 and 2013, respectively	4	-13	-6	23
Other, net of tax (benefit) expense of ($5) and $2 for the three months ended June 30, 2014 and 2013, respectively, and ($2) and $0 for the six months ended June 30, 2014 and 2013, respectively	-18	3	-7	-1
Total other comprehensive (loss) income, net of tax	-199	-8	-169	45
Comprehensive income	$321	$582	$907	$1,187

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Tax expense (benefit) on currency translation adjustments	($12)	($11)	($8)	($4)
Tax expense pension and other employee benefits	14	20	23	44
Tax expense (benefit) on hedging activities	4	-8	-2	11
Tax expense (benefit) on Other	($5)	$2	($2)	$0

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets	'	'
Cash and equivalents	$1,866	$2,733
Accounts and other current receivables, net	2,914	2,911
Inventories	3,836	3,499
Prepaid expenses and other	871	861
Total current assets	9,487	10,004
Property, plant and equipment, net	8,152	7,832
Other assets	'	'
Goodwill	4,226	4,205
Other intangible assets, net	2,329	2,294
Other	1,435	1,534
Total other assets	7,990	8,033
Total assets	25,629	25,869
Current liabilities	'	'
Short-term debt	186	181
Current maturities of long-term debt and lease obligations	1,125	859
Accounts payable and accrued liabilities	4,484	4,866
Total current liabilities	5,795	5,906
Long-term debt and lease obligations	7,528	8,126
Other long-term liabilities	3,619	3,351
Commitments and contingencies	'	'
Equity	'	'
Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2014 and 2013	683	683
Common stock in treasury, at cost, 141,827,303 shares in 2014 and 140,456,989 shares in 2013	-8,039	-7,914
Additional contributed capital	5,785	5,818
Retained earnings	12,378	11,852
Accumulated other comprehensive loss	-2,145	-1,976
Total Baxter International Inc. (Baxter) shareholders' equity	8,662	8,463
Noncontrolling interests	25	23
Total equity	8,687	8,486
Total liabilities and equity	$25,629	$25,869

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value	$1	$1
Common stock, authorized	2,000,000,000	2,000,000,000
Common stock, issued	683,494,944	683,494,944
Treasury stock, shares	141,827,303	140,456,989

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operations	'	'
Net income	$1,076	$1,142
Adjustments	'	'
Depreciation and amortization	489	366
Deferred income taxes	-31	-63
Stock compensation	72	72
Realized excess tax benefits from stock issued under employee benefit plans	-17	-19
Net periodic pension benefit and OPEB costs	141	187
Infusion pump and other product-related charges	93	'
Other	74	52
Changes in balance sheet items	'	'
Accounts and other current receivables, net	3	12
Inventories	-360	-306
Accounts payable and accrued liabilities	-222	-171
Business optimization and infusion pump payments	-83	-52
Other	-77	-71
Cash flows from operations	1,158	1,149
Cash flows from investing activities	'	'
Capital expenditures	-844	-639
Acquisitions and investments, net of cash acquired	-176	-87
Divestitures and other investing activities	94	10
Cash flows from investing activities	-926	-716
Cash flows from financing activities	'	'
Issuances of debt, net of issuance costs	34	3,489
Payments of obligations	-526	-304
Increase in debt with original maturities of three months or less, net	150	'
Cash dividends on common stock	-531	-490
Proceeds and realized excess tax benefits from stock issued under employee benefit plans	249	341
Purchases of treasury stock	-450	-717
Other	2	-24
Cash flows from financing activities	-1,072	2,295
Effect of foreign exchange rate changes on cash and equivalents	-27	-9
(Decrease) increase in cash and equivalents	-867	2,719
Cash and equivalents at beginning of period	2,733	3,270
Cash and equivalents at end of period	$1,866	$5,989

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Basis of Presentation	'
	1. BASIS OF PRESENTATION
	The unaudited interim condensed consolidated financial statements of Baxter International Inc. and its subsidiaries (the company or Baxter) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (GAAP) in the United States have been condensed or omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Annual Report).
	In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments necessary for a fair statement of the interim periods. All such adjustments, unless otherwise noted herein, are of a normal, recurring nature. The results of operations for the interim period are not necessarily indicative of the results of operations to be expected for the full year.
	Certain reclassifications have been made to conform the prior period condensed consolidated financial statements to the current period presentation.
	Planned spin-off of biopharmaceuticals business
	On March 27, 2014 Baxter announced plans to create two separate, independent global healthcare companies – one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. The transaction is intended to take the form of a tax-free distribution to Baxter shareholders of publicly traded stock in the new biopharmaceuticals company. The transaction is expected to be completed by mid-year 2015, subject to market, regulatory and certain other conditions, including final approval by the Baxter Board of Directors, receipt of a favorable opinion and/or rulings with respect to the tax-free nature of the transaction, and the effectiveness of a Form 10 registration statement that will be filed with the SEC. Subsequent to the separation, the historical results of the biopharmaceuticals business will be presented as discontinued operations. During the second quarter of 2014, the company incurred $22 million of separation-related costs in marketing and administrative expenses.
	New accounting standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU 2014-09 will be effective for the company beginning on January 1, 2017. Early adoption is not permitted. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The company is currently evaluating the impact of adopting the new revenue standard on its consolidated financial statements.

Supplemental_Financial_Informa

Supplemental Financial Information	6 Months Ended
	Jun. 30, 2014
Supplemental Financial Information	'
	2. SUPPLEMENTAL FINANCIAL INFORMATION
	Net interest expense
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Interest expense, net of capitalized interest		$47			$24			$95			$55
	Interest income		(5	)		(7	)		(10	)		(13	)
	Net interest expense		$42			$17			$85			$42
	Inventories
		June 30,			December 31,
	(in millions)	2014			2013
	Raw materials		$   829			$   920
	Work in process		1,221			1,136
	Finished goods		1,786			1,443
	Inventories		$3,836			$3,499
	Property, plant and equipment, net
		June 30,			December 31,
	(in millions)	2014			2013
	Property, plant and equipment, at cost		$14,366			$13,795
	Accumulated depreciation		(6,214	)		(5,963	)
	Property, plant and equipment (PP&E), net		$  8,152			$  7,832

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share	'
	3. EARNINGS PER SHARE
	The numerator for both basic and diluted earnings per share (EPS) is net income. The denominator for basic EPS is the weighted-average number of common shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units (RSUs) and performance share units (PSUs) is reflected in the denominator for diluted EPS using the treasury stock method.
	The following is a reconciliation of basic shares to diluted shares.
		Three months ended				Six months ended
		June 30,				June 30,
	(in millions)	2014		2013		2014		2013
	Basic shares		542		543		542		543
	Effect of dilutive securities		6		6		6		7
	Diluted shares		548		549		548		550
	The effect of dilutive securities included unexercised stock options, unvested RSUs and contingently issuable shares related to granted PSUs. The computation of diluted EPS excluded 11 million and 9 million equity awards for the second quarter and the six months ended June 30, 2014, respectively, and 6 million equity awards for both the second quarter and the six months ended June 30, 2013, because their inclusion would have had an anti-dilutive effect on diluted EPS. Refer to Note 8 for additional information regarding items impacting basic shares.

Acquisitions_and_Collaboration

Acquisitions and Collaborations	6 Months Ended
	Jun. 30, 2014
Acquisitions and Collaborations	'
	4. ACQUISITIONS AND COLLABORATIONS
	Acquisitions
	The following table summarizes the fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the company’s significant acquisitions during the first half of 2014.
	(in millions)	Chatham		AesRx
	Consideration transferred
	Cash		$  70		$15
	Contingent payments		77		65
	Fair value of consideration transferred		$147		$80
	Assets acquired and liabilities assumed
	Other intangible assets – IPR&D		$  74		$78
	Total identifiable net assets		74		78
	Goodwill		73		2
	Total assets acquired and liabilities assumed		$147		$80
	While the valuations of consideration transferred and total assets acquired and liabilities assumed are substantially complete, measurement period adjustments may be recorded in the future as the company finalizes its fair value estimates. Pro forma financial information has not been included because these acquisitions, individually and in the aggregate, did not have a material impact on the company’s financial position or results of operations as of and for the three and six months ended June 30, 2014.
	Additional information regarding the above acquisitions has been provided below.
	Chatham Therapeutics, LLC
	In April 2014, Baxter acquired all of the outstanding membership interests in Chatham Therapeutics, LLC (Chatham Therapeutics), obtaining Chatham Therapeutics’ gene therapy programs related to the development and commercialization of treatments for hemophilia.
	Baxter made an initial payment of $70 million, and may make additional payments of up to $560 million in payments related to the achievement of development, regulatory and first commercial sale milestones, in addition to sales milestones of up to $780 million. The estimated fair value of the contingent payment liabilities at the acquisition date was $77 million, which was recorded in other long-term liabilities as part of the consideration transferred, and based on the probability of achieving the specified milestones and the discounting of expected future cash flows.
	Baxter allocated $74 million of the total consideration to acquired IPR&D, which will be accounted for as an indefinite-lived intangible asset, with the residual consideration of $73 million recorded as goodwill. The acquired IPR&D primarily relates to Chatham Therapeutics’ hemophilia A (FVIII) program, which was in preclinical stage at the time of the acquisition and is expected to be completed in approximately 10 years. The value of the IPR&D was calculated using cash flow projections adjusted for the inherent technical, regulatory, commercial and obsolescence risks in such activities, discounted at a rate of 12%. Additional research and development will be required prior to technological feasibility, and as of the acquisition date, incremental research and development costs are projected to be in excess of $130 million. The goodwill, which may be deductible for tax purposes depending on the ultimate resolution of the contingent payment liabilities, includes the value of potential future technologies as well as the overall strategic benefits of the acquisition to Baxter in the hemophilia market and is included in the BioScience segment.
	AesRx, LLC
	In June 2014, Baxter acquired all of the outstanding membership interests in AesRx, LLC (AesRx), obtaining AesRx’s program related to the development and commercialization of treatments for sickle cell disease.
	Baxter made an initial payment of $15 million, and may make additional payments of up to $278 million related to the achievement of development and regulatory milestones, in addition to sales milestones of up to $550 million. The estimated fair value of the contingent payment liabilities at the acquisition date was $65 million, which was recorded in other long-term liabilities as part of the consideration transferred, and based on the probability of achieving the specified milestones and the discounting of expected future cash flows.
	Baxter allocated $78 million of the total consideration to acquired IPR&D, which will be accounted for as indefinite-lived intangible assets, with the residual consideration of $2 million recorded as goodwill. The acquired IPR&D relates to AesRx’s sickle cell disease program, which was in Phase II clinical trials at the time of the acquisition, and is expected to be completed in approximately five years. The value of IPR&D was calculated using cash flow projections adjusted for the inherent technical, regulatory, commercial and obsolescence risks in such activities, discounted at a rate of 15.5%. Additional research and development will be required prior to technological feasibility, and as of the acquisition date, incremental research and development costs are projected to be in excess of $40 million.
	Gambro AB Acquisition
	On September 6, 2013, Baxter acquired 100 percent of the voting equity interests in Indap Holding AB, the holding company for Gambro AB (Gambro), a privately held dialysis product company based in Lund, Sweden.
	In the first quarter of 2014, the company adjusted its preliminary estimates of the fair value of assets acquired and liabilities assumed as of the acquisition date to reflect updated valuations. The measurement period adjustments included a $16 million reduction to property, plant and equipment and $4 million of working capital adjustments. The adjustments resulted in a corresponding increase in goodwill of $16 million and $4 million decrease to the fair value of consideration transferred. There were no measurement period adjustments in the second quarter of 2014, and the first quarter adjustment did not have a material impact on Baxter’s results of operations for the six months ended June 30, 2014.
	The company incurred charges of $29 million and $63 million in the second quarter and six months ended June 30, 2014 related to the integration of Gambro, including a $19 million loss on the divestiture of Baxter’s legacy Continuous Renal Replacement Therapy (CRRT) business in the six months ended June 30, 2014. These charges were recorded in marketing and administrative expenses and other expense (income), net. Additionally, the company incurred charges of $23 million and $40 million in the second quarter and six months ended June 30, 2013 related to pre-acquisition costs associated with the planned acquisition of Gambro, which the company recorded in marketing and administrative expenses.
	Collaborations
	Coherus Biosciences, Inc.
	In August 2013, Baxter and Coherus Biosciences, Inc. (Coherus) entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil, and certain other markets. Baxter also has specified rights to include additional products in the collaboration. Baxter recognized research and development charges totaling $60 million during the first half of 2014 related to milestone payments pursuant to the collaboration arrangement, of which $35 million was recognized during the second quarter of 2014. As of June 30, 2014, Baxter may make additional payments of up to $94 million relating to the achievement of development and regulatory milestones, in addition to royalties based on net sales.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, Net	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets, Net	'
	5. GOODWILL AND OTHER INTANGIBLE ASSETS, NET
	Impairment tests for goodwill and intangible assets not subject to amortization are performed annually in the fourth quarter, or sooner if indicators of impairment exist. Intangible assets subject to amortization are tested for impairment when indicators of impairment exist.
	Goodwill
	The following is a reconciliation of goodwill by business segment.
	(in millions)	BioScience			Medical Products			Total
	Balance as of December 31, 2013		$   991			$3,214			$4,205
	Additions		75			4			79
	Currency translation and other adjustments		(4	)		(54	)		(58	)
	Balance as of June 30, 2014		$1,062			$3,164			$4,226
	Goodwill additions are primarily related to the acquisition of Chatham Therapeutics in the second quarter of 2014. As of June 30, 2014, there were no accumulated goodwill impairment losses.
	Other intangible assets, net
	Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. Intangible assets not subject to amortization include a trademark with an indefinite life and acquired IPR&D associated with products that have not yet received regulatory approval.
	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived			Total
		including patents			intangible assets			intangible assets
	June 30, 2014
	Gross other intangible assets		$2,123			$461			$612			$3,196
	Accumulated amortization		(731	)		(136	)		—			(867	)
	Other intangible assets, net		$1,392			$325			$612			$2,329
	December 31, 2013
	Gross other intangible assets		$2,144			$494			$465			$3,103
	Accumulated amortization		(665	)		(144	)		—			(809	)
	Other intangible assets, net		$1,479			$350			$465			$2,294
	The amortization expense for these intangible assets was $47 million and $25 million in the three months ended June 30, 2014 and 2013, respectively, and $90 million and $50 million for the six months ended June 30, 2014 and 2013, respectively. The anticipated annual amortization expense for intangible assets recorded as of June 30, 2014 is $182 million in 2014, $183 million in 2015, $179 million in 2016, $161 million in 2017, $157 million in 2018 and $143 million in 2019.
	The increase in indefinite-lived intangible assets in the first six months of 2014 was primarily related to the acquisitions of Chatham Therapeutics and AesRx in the second quarter of 2014.

Infusion_Pump_and_Business_Opt

Infusion Pump and Business Optimization Charges	6 Months Ended
	Jun. 30, 2014
Infusion Pump and Business Optimization Charges	'
	6. INFUSION PUMP AND BUSINESS OPTIMIZATION CHARGES
	Infusion pump charges
	The company is undertaking a field corrective action with respect to the SIGMA Spectrum Infusion Pump, which is predominantly sold in the United States. The FDA categorized the action as a Class 1 recall during the second quarter of 2014. Remediation is expected to include software-related corrections and in a limited number of cases a replacement pump, with an expected completion date of March 2016. The company recorded a charge of $93 million related primarily to cash costs associated with remediation efforts, which the company believes to be an adequate reserve as of June 30, 2014. However, it is possible that substantial additional cash and non-cash charges may be required in future periods based on new information or changes in estimates.
	From 2005 through 2013, the company recorded total charges and adjustments of $888 million related to COLLEAGUE and SYNDEO infusion pumps, including $725 million of cash costs and $163 million principally related to asset impairments. The company had $83 million of the cash reserves remaining as of December 31, 2013. During the first half of 2014, the company utilized $13 million of the cash reserves, with a remaining cash reserve of $70 million as of June 30, 2014. The reserve for COLLEAGUE and SYNDEO remediation activities in the United States has been substantially utilized, with remaining reserves primarily related to remediation activities outside of the United States continuing to be utilized through 2015.
	Business optimization charges
	From 2009 through 2013 the company recorded total charges of $992 million primarily related to costs associated with optimizing the company’s overall cost structure on a global basis, as the company streamlined its international operations, rationalized its manufacturing facilities, enhanced its general and administrative infrastructure and re-aligned certain research and development activities. The total charges included cash costs of $689 million, principally pertaining to severance and other employee-related costs, and $303 million related to asset impairments. The company had $288 million of the cash reserves remaining as of December 31, 2013. Refer to the 2013 Annual Report for further information about these charges.
	In the second quarter of 2014, the company recorded a net benefit of $32 million primarily related to adjustments to previous business optimization reserves that are no longer probable of being utilized. In the first half of 2014, the company recorded total adjustments of $37 million to previous business optimization charges that are no longer probable of being utilized, partially offset by additional charges of $33 million primarily related to severance and employee-related costs, and inclusive of Gambro post-acquisition restructuring activities.
	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserves as of December 31, 2013	$	288
	Charges		32
	Reserve adjustments		(35	)
	Utilization		(70	)
	Reserves as of June 30, 2014	$	215
	The reserves are expected to be substantially utilized by the end of 2015. The company believes that these reserves are adequate. However, adjustments may be recorded in the future as the programs are completed.

Debt_Financial_Instruments_and

Debt, Financial Instruments and Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Debt, Financial Instruments and Fair Value Measurements	'
	7. DEBT, FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
	Securitization arrangement
	The following is a summary of the activity relating to the company’s securitization arrangement in Japan.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Sold receivables at beginning of period		$109			$120			$114			$157
	Proceeds from sales of receivables		117			131			240			255
	Cash collections (remitted to the owners of the receivables)		(120	)		(123	)		(249	)		(264	)
	Effect of currency exchange rate changes		—			1			1			(19	)
	Sold receivables at end of period		$106			$129			$106			$129
	The net losses relating to the sales of receivables were immaterial for each period. Refer to the 2013 Annual Report for further information regarding the company’s securitization agreements.
	Credit facilities and commercial paper
	As of June 30, 2014, there were no outstanding borrowings under the company’s primary and Euro-denominated revolving credit facilities. As of December 31, 2013, there were no outstanding borrowings under the company’s primary revolving credit facility and approximately $124 million outstanding under the Euro-denominated revolving credit facility. Refer to the 2013 Annual Report for further discussion of the company’s credit facilities.
	In July 2014, the company amended its primary and Euro-denominated revolving credit facilities to extend the termination date of the facilities to December 31, 2015. There were no other material changes to the terms of the facilities as a result of the amendments.
	During the first six months of 2014, the company issued and redeemed commercial paper, of which $150 million was outstanding as of June 30, 2014 with a weighted-average interest rate of 0.165%. This commercial paper is classified as short-term debt. The company did not have any commercial paper outstanding as of December 31, 2013.
	Concentrations of credit risk
	The company invests excess cash in certificates of deposit or money market funds and diversifies the concentration of cash among different financial institutions. With respect to financial instruments, where appropriate, the company has diversified its selection of counterparties, and has arranged collateralization and master-netting agreements to minimize the risk of loss.
	The company continues to do business with foreign governments in certain countries, including Greece, Spain, Portugal and Italy, that have experienced a deterioration in credit and economic conditions. As of June 30, 2014, the company’s net accounts receivable from the public sector in Greece, Spain, Portugal and Italy totaled $450 million (of which $37 million related to Greece).
	Global economic conditions and liquidity issues in certain countries have resulted, and may continue to result, in delays in the collection of receivables and credit losses. Governmental actions and customer-specific factors may also require the company to re-evaluate the collectibility of its receivables and the company could potentially incur additional credit losses. These conditions may also impact the stability of the Euro.
	Derivatives and hedging activities
	The company operates on a global basis and is exposed to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange and interest rates. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs.
	The company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities, forecasted transactions and net assets denominated in the Euro, Japanese Yen, British Pound, Australian Dollar, Canadian Dollar, Brazilian Real, Colombian Peso, and Swedish Krona. The company manages its foreign currency exposures on a consolidated basis, which allows the company to net exposures and take advantage of any natural offsets. In addition, the company uses derivative and nonderivative instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and equity volatility resulting from foreign exchange. Financial market and currency volatility may limit the company’s ability to cost-effectively hedge these exposures.
	The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company’s policy is to manage interest costs using a mix of fixed- and floating-rate debt that the company believes is appropriate. To manage this mix in a cost-efficient manner, the company periodically enters into interest rate swaps in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount.
	The company does not hold any instruments for trading purposes and none of the company’s outstanding derivative instruments contain credit-risk-related contingent features.
	All derivative instruments are recognized as either assets or liabilities at fair value in the condensed consolidated balance sheets and are classified as short-term or long-term based on the scheduled maturity of the instrument. Based upon the exposure being hedged, the company designates its hedging instruments as cash flow or fair value hedges.
	Cash Flow Hedges
	The company may use options, including collars and purchased options, forwards and cross-currency swaps to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The company periodically uses forward-starting interest rate swaps and treasury rate locks to hedge the risk to earnings associated with movements in interest rates relating to anticipated issuances of debt. Certain other firm commitments and forecasted transactions are also periodically hedged.
	For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is accumulated in accumulated other comprehensive income (AOCI) and then recognized in earnings consistent with the underlying hedged item. Option premiums or net premiums paid are initially recorded as assets and reclassified to other comprehensive income (OCI) over the life of the option, and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in net sales, cost of sales, and net interest expense, and primarily relate to forecasted third-party sales denominated in foreign currencies, forecasted intercompany sales denominated in foreign currencies, and anticipated issuances of debt, respectively.
	The notional amounts of foreign exchange contracts were $1.6 billion and $2.1 billion as of June 30, 2014 and December 31, 2013, respectively. There were no interest rate contacts designated as cash flow hedges outstanding as of June 30, 2014 and December 31, 2013. The maximum term over which the company has cash flow hedge contracts in place related to forecasted transactions as of June 30, 2014 is 18 months.
	Fair Value Hedges
	The company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These instruments hedge the company’s earnings from changes in the fair value of debt due to fluctuations in the designated benchmark interest rate. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in net interest expense, as they hedge the interest rate risk associated with certain of the company’s fixed-rate debt.
	The total notional amount of interest rate contracts designated as fair value hedges was $1.7 billion and $1.2 billion as of June 30, 2014 and December 31, 2013, respectively.
	Dedesignations
	If it is determined that a derivative or nonderivative hedging instrument is no longer highly effective as a hedge, the company discontinues hedge accounting prospectively. If the company removes the cash flow hedge designation because the hedged forecasted transactions are no longer probable of occurring, any gains or losses are immediately reclassified from AOCI to earnings. Gains or losses relating to terminations of effective cash flow hedges in which the forecasted transactions are still probable of occurring are deferred and recognized consistent with the loss or income recognition of the underlying hedged items.
	There were no hedge dedesignations in the first six months of 2014 resulting from changes in the company’s assessment of the probability that the hedged forecasted transactions would occur. In the first half of 2013, the company had $1 billion of interest rate contracts designated as cash flow hedges that matured or were terminated, resulting in a net gain of $5 million that was deferred in AOCI. In the second quarter of 2013, the company determined that certain forecasted transactions associated with these contracts were no longer probable of occurring and therefore dedesignated the hedge relationship, which, together with ineffectiveness, resulted in the immediate reclassification of a net gain of $11 million from AOCI to net interest expense. The remaining deferred net loss of $6 million from the matured or terminated interest rate contracts is being amortized to net interest expense against the related accrued interest payments.
	If the company terminates a fair value hedge, an amount equal to the cumulative fair value adjustment to the hedged items at the date of termination is amortized to earnings over the remaining term of the hedged item. There were no fair value hedges terminated during the first half of 2014 and 2013.
	Undesignated Derivative Instruments
	The company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments are generally not formally designated as hedges, and the change in fair value, which substantially offsets the change in book value of the hedged items, is recorded directly to other expense (income), net. The terms of these instruments generally do not exceed one month.
	The total notional amount of undesignated derivative instruments was $397 million as of June 30, 2014 and $381 million as of December 31, 2013. In the fourth quarter of 2012 and the first quarter of 2013, the company entered into option contracts with a total notional amount of $3.7 billion to hedge anticipated foreign currency cash outflows associated with the planned acquisition of Gambro. These contracts matured in June 2013, and in the second quarter of 2013, the company entered into undesignated forward contracts with a total notional amount of $1.5 billion also to hedge anticipated foreign currency cash outflows associated with the planned acquisition of Gambro. These contracts matured in the third quarter of 2013.
	The company recorded losses of $55 million and $72 million in the three and six months ended June 30, 2013, respectively, associated with the Gambro-related option and forward contracts, which more than offset net gains on other undesignated derivative instruments.
	Gains and Losses on Derivative Instruments
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended June 30, 2014 and 2013.
		Gain (loss) recognized in OCI						Location of gain (loss)			Gain (loss) reclassified from AOCI
											into income
	(in millions)	2014			2013			in income statement			2014			2013
	Cash flow hedges
	Interest rate contracts		$—			$21			Net interest expense			$—			$11
	Foreign exchange contracts		1			1			Net sales			1			(1	)
	Foreign exchange contracts		5			(17	)		Cost of sales			(3	)		16
	Total		$  6			$  5						$ (2	)		$26
					Gain (loss) recognized in income
	(in millions)	Location of gain (loss) in income statement			2014			2013
	Fair value hedges
	Interest rate contracts		Net interest expense			$ 17			$(21	)
	Undesignated derivative instruments
	Foreign exchange contracts		Other expense (income), net			$(22	)		$(44	)
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the six months ended June 30, 2014 and 2013.
		Gain (loss) recognized in OCI						Location of gain (loss)			Gain (loss) reclassified from AOCI
											into income
	(in millions)	2014			2013			in income statement			2014			2013
	Cash flow hedges
	Interest rate contracts		$—			$26			Net interest expense			$(1	)		$11
Foreign exchange contracts		—			—			Net sales			1			(1	)
Foreign exchange contracts		(6	)		36			Cost of sales			2			18
Total		$ (6	)		$62						$ 2			$28
				Gain (loss) recognized in income
(in millions)	Location of gain (loss) in income statement			2014			2013
Fair value hedges
Interest rate contracts		Net interest expense			$ 31			$(26	)
Undesignated derivative instruments
Foreign exchange contracts		Other expense (income), net			$(10	)		$(45	)
For the company’s fair value hedges, equal and offsetting losses of $17 million and $31 million were recognized in net interest expense in the second quarter and first half of 2014, respectively, and equal and offsetting gains of $21 million and $26 million were recognized in net interest expense in the second quarter and first half of 2013, respectively, as adjustments to the underlying hedged item, fixed-rate debt. Ineffectiveness related to the company’s cash flow and fair value hedges for the six months ended June 30, 2014 was not material.
As of June 30, 2014, $3 million of deferred, net after-tax losses on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings.
Fair Values of Derivative Instruments
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2014.
	Derivatives in asset positions						Derivatives in liability positions
(in millions)	Balance sheet location			Fair value			Balance sheet location			Fair value
Derivative instruments designated as hedges
Interest rate contracts		Other long-term assets			$52
Foreign exchange contracts		Prepaid expenses and other			19
Foreign exchange contracts		Other long-term assets			2			Accounts payable			4
								and accrued liabilities
Total derivative instruments designated as hedges					$73						$4
Undesignated derivative instruments
Foreign exchange contracts		Prepaid expenses and other			$—			Accounts payable			$1
								and accrued liabilities
Total derivative instruments					$73						$5
The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2013.
	Derivatives in asset positions						Derivatives in liability positions
(in millions)	Balance sheet location			Fair value			Balance sheet location			Fair value
Derivative instruments designated as hedges
Interest rate contracts		Other long-term assets			$35			Other long-term liabilities			$14
Foreign exchange contracts		Prepaid expenses and other			37			Accounts payable			7
								and accrued liabilities
Total derivative instruments designated as hedges					$72						$21
Undesignated derivative instruments
Foreign exchange contracts		Prepaid expenses and other			$—			Accounts payable			$  1
								and accrued liabilities
Total derivative instruments					$72						$22
While the company’s derivatives are all subject to master netting arrangements, the company presents its assets and liabilities related to derivative instruments on a gross basis within the condensed consolidated balance sheets. Additionally, the company is not required to post collateral for any of its outstanding derivatives.
The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty:
	June 30, 2014						December 31, 2013
(in millions)	Asset			Liability			Asset			Liability
Gross amounts recognized in the consolidated balance sheet		$ 73			$   5			$ 72			$ 22
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(5	)		(5	)		(17	)		(17	)
Total		$ 68			$  —			$ 55			$   5
Fair value measurements
The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets.
				Basis of fair value measurement
(in millions)	Balance as of			Quoted prices in			Significant other			Significant
				active markets for			observable inputs			unobservable
	June 30, 2014			identical assets
							(Level 2)			inputs
				(Level 1)
										(Level 3)
Assets
Foreign currency hedges		$  21			$  —			$21			$  —
Interest rate hedges		52			—			52			—
Available-for-sale securities
Equity securities		100			100			—			—
Foreign government debt securities		18			—			18			—
Total assets		$191			$100			$91			$  —
Liabilities
Foreign currency hedges		$    5			$  —			$  5			$  —
Contingent payments related to acquisitions		523			—			—			523
Total liabilities		$528			$  —			$  5			$523
				Basis of fair value measurement
(in millions)	Balance as of			Quoted prices in			Significant other			Significant
	December 31, 2013			active markets for			observable inputs			unobservable
				identical assets
							(Level 2)			inputs
				(Level 1)
										(Level 3)
Assets
Foreign currency hedges		$  37			$  —			$37			$  —
Interest rate hedges		35			—			35			—
Available-for-sale securities
Equity securities		102			102			—			—
Foreign government debt securities		18			—			18			—
Total assets		$192			$102			$90			$  —
Liabilities
Foreign currency hedges		$    8			$  —			$  8			$  —
Interest rate hedges		14			—			14			—
Contingent payments related to acquisitions and investments		340			—			—			340
Total liabilities		$362			$  —			$22			$340
As of June 30, 2014, cash and equivalents of $1.9 billion included money market funds of approximately $25 million, which would be considered Level 2 in the fair value hierarchy.
For assets that are measured using quoted prices in active markets, the fair value is the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The majority of the derivatives entered into by the company are valued using internal valuation techniques as no quoted market prices exist for such instruments. The principal techniques used to value these instruments are discounted cash flow and Black-Scholes models. The key inputs are considered observable and vary depending on the type of derivative, and include contractual terms, interest rate yield curves, foreign exchange rates and volatility. The fair values of foreign government debt securities are obtained from pricing services or broker/dealers who use proprietary pricing applications, which include observable market information for like or same securities.
Contingent payments related to acquisitions consist of development and commercial milestone payments, in addition to sales-based payments, and are valued using discounted cash flow techniques. The fair value of development and commercial milestone payments reflects management’s expectations of probability of payment, and increases as the probability of payment increases or expectation of timing of payments is accelerated. As of June 30, 2014, management’s expected weighted-average probability of payment for development and commercial milestone payments decreased to approximately 27% largely due to the contingent payments related to the acquisitions completed in the quarter. The fair value of sales-based payments is based upon probability-weighted future revenue estimates, and increases as revenue estimates increase, probability weighting of higher revenue scenarios increase or expectation of timing of payment is accelerated.
At June 30, 2014, the company held available-for-sale equity securities that had an amortized cost basis and fair value of $118 million and $100 million, respectively. The company had net unrealized losses of $18 million, comprised of unrealized losses of $47 million, which the company believes to be temporary in nature, and unrealized gains of $29 million. At December 31, 2013, the amortized cost basis and fair value of the available-for-sale equity securities was $111 million and $102 million, respectively. The company had net unrealized losses of $9 million, comprised of unrealized losses of $31 million, which the company believes to be temporary in nature, and unrealized gains of $22 million.
Unrealized losses on equity securities of $45 million and $30 million as of June 30, 2014 and December 31, 2013, respectively, relate to Baxter’s holdings in the common stock of Onconova Therapeutics, Inc. (Onconova). The amortized cost basis was $59 million and $60 million as of June 30, 2014 and December 31, 2013, respectively. Onconova common stock has been in a loss position for less than 12 months and Baxter believes the losses are temporary in nature due to future development opportunities for Onconova’s most advanced product candidate, rigosertib, in addition to its other candidates in clinical trials and pre-clinical stages.
The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consists of contingent payments related to acquisitions.
(in millions)	Contingent
	payments
Fair value as of December 31, 2013		$340
Additions		142
Net losses recognized in earnings		43
CTA		(2	)
Fair value as of June 30, 2014		$523
The company’s additions in 2014 relate to the contingent payment liabilities of $77 million associated with the acquisition of Chatham Therapeutics and $65 million associated with the acquisition of AesRx. The net loss recognized in earnings primarily relates to an increase in the estimated fair value of contingent payment liabilities for certain milestones associated with the 2013 acquisition of the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals and Ipsen Pharma S.A.S. The loss was reported in other expense (income), net. The contingent liabilities were increased based on updated information indicating that the probability of achieving certain sales levels, and the resulting sales-based payments, was higher than previously expected.
Book Values and Fair Values of Financial Instruments
In addition to the financial instruments that the company is required to recognize at fair value on the condensed consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. For these financial instruments, the following table provides the values recognized on the condensed consolidated balance sheets and the approximate fair values as of June 30, 2014 and December 31, 2013.
	Book values						Approximate fair values
(in millions)	2014			2013			2014			2013
Assets
Long-term insurance receivables	$	2		$	2		$	2		$	2
Investments		63			53			64			53
Liabilities
Short-term debt		186			181			186			181
Current maturities of long-term debt and lease obligations		1,125			859			1,143			862
Long-term debt and lease obligations		7,528			8,126			7,869			8,298
Long-term litigation liabilities		55			72			54			70
The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of June 30, 2014 and December 31, 2013.
				Basis of fair value measurement
(in millions)	Fair value as of			Quoted prices in			Significant other			Significant
	30-Jun-14			active markets for			observable inputs			unobservable
				identical assets			(Level 2)			inputs
				(Level 1)						(Level 3)
Assets
Long-term insurance receivables		$       2			$—			$     —			$  2
Investments		64			—			19			45
Total assets		$     66			$—			$     19			$47
Liabilities
Short-term debt		$   186			$—			$   186			$—
Current maturities of long-term debt and lease obligations		1,143			—			1,143			—
Long-term debt and lease obligations		7,869			—			7,869			—
Long-term litigation liabilities		54			—			—			54
Total liabilities		$9,252			$—			$9,198			$54
				Basis of fair value measurement
(in millions)	Fair value as of			Quoted prices in			Significant other			Significant
	December 31, 2013			active markets for			observable inputs			unobservable
				identical assets			(Level 2)			inputs
				(Level 1)						(Level 3)
Assets
Long-term insurance receivables		$       2			$—			$     —			$  2
Investments		53			—			17			36
Total assets		$     55			$—			$     17			$38
Liabilities
Short-term debt		$   181			$—			$   181			$—
Current maturities of long-term debt and lease obligations		862			—			862			—
Long-term debt and lease obligations		8,298			—			8,298			—
Long-term litigation liabilities		70			—			—			70
Total liabilities		$9,411			$—			$9,341			$70
The estimated fair values of long-term insurance receivables and long-term litigation liabilities were computed by discounting the expected cash flows based on currently available information, which in many cases does not include final orders or settlement agreements. The discount factors used in the calculations reflect the non-performance risk of the insurance providers and the company, respectively.
Investments in 2014 and 2013 included certain cost method investments and held-to-maturity debt securities.
The fair value of held-to-maturity debt securities is calculated using a discounted cash flow model that incorporates observable inputs, including interest rate yields, which represents a Level 2 basis of fair value measurement.
In determining the fair value of cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement.
The estimated fair values of current and long-term debt were computed by multiplying price by the notional amount of the respective debt instrument. Price is calculated using the stated terms of the respective debt instrument and yield curves commensurate with the company’s credit risk. The carrying values of the other financial instruments approximate their fair values due to the short-term maturities of most of these assets and liabilities.
In the first quarter of 2014, the company recognized a $44 million gain related to the sale of certain equity method investments in other expense (income), net.

Shareholders_Equity

Shareholders' Equity	6 Months Ended
	Jun. 30, 2014
Shareholders' Equity	'
	8. SHAREHOLDERS’ EQUITY
	Stock-based compensation
	Stock compensation expense totaled $41 million and $40 million for the three months ended June 30, 2014 and 2013, respectively, and $72 million for both six month periods ended June 30, 2014 and 2013. Over 70% of stock compensation expense is classified in marketing and administrative expenses with the remainder classified in cost of sales and research and development expenses.
	In March 2014, the company awarded its annual stock compensation grants, which consisted of 6.5 million stock options, 854,000 RSUs and 335,000 PSUs. In June 2014, the company awarded 283,000 RSUs in connection with the planned separation of Baxter’s biopharmaceutical and medical products businesses.
	Stock Options
	The fair value of stock options is determined using the Black-Scholes model. The company’s expected volatility assumption is based on a weighted-average of the historical volatility of Baxter’s stock and the implied volatility from traded options on Baxter’s stock, with historical volatility more heavily weighted.
	The weighted-average assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows.
		Six months ended
		June 30,
		2014		2013
	Expected volatility		24%		25%
	Expected life (in years)		5.5		5.5
	Risk-free interest rate		1.70%		0.90%
	Dividend yield		2.80%		2.60%
	Fair value per stock option		$12		$12
	The total intrinsic value of stock options exercised was $34 million and $46 million during the second quarters of 2014 and 2013, respectively, and $79 million and $107 million during the six months ended June 30, 2014 and 2013, respectively.
	As of June 30, 2014, the unrecognized compensation cost related to all unvested stock options of $95 million is expected to be recognized as expense over a weighted-average period of 1.9 years.
	Restricted Stock Units
	The fair value of RSUs is determined based on the quoted price of the company’s common stock on the date of the grant. As of June 30, 2014, the unrecognized compensation cost related to all unvested RSUs of $110 million is expected to be recognized as expense over a weighted-average period of 1.9 years.
	Performance Share Units
	As part of an overall periodic evaluation of the company’s stock compensation programs, the company changed the vesting condition for 50% of the PSUs granted to senior management beginning with its 2013 annual equity awards. The vesting condition for these PSUs is based on return on invested capital, with annual performance targets set at the beginning of the year for each tranche of the award during the three-year service period. The holder of these PSUs is entitled to receive a number of shares of common stock equal to a percentage, ranging from 0% to 200%, of the PSU granted, depending on the actual results compared to the annual performance targets.
	Compensation cost for these PSUs is measured based on the fair value of the awards on the date that the specific vesting terms for each tranche of the award are established. The fair value of the awards is determined based on the quoted price of the company’s stock on the grant date for each tranche of the award. The compensation cost for these PSUs is adjusted at each reporting date to reflect the estimated probability of achieving the vesting condition. The probability of achieving the vesting conditions has not materially changed during the second quarter of 2014.
	The fair value of the remaining PSUs is determined using a Monte Carlo model. A Monte Carlo model uses stock price volatility and other variables to estimate the probability of satisfying the market conditions and the resulting fair value of the award. The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
		Six months ended
		June 30,
		2014		2013
	Baxter volatility		20%		21%
	Peer group volatility		13% – 58%		13% – 38%
	Correlation of returns		0.23 – 0.66		0.37 – 0.62
	Risk-free interest rate		0.70%		0.30%
	Fair value per PSU		$57		$67
	As of June 30, 2014, the unrecognized compensation cost related to all granted unvested PSUs of $22 million is expected to be recognized as expense over a weighted-average period of 1.4 years.
	Stock repurchases
	As authorized by the board of directors, the company repurchases its stock depending upon the company’s cash flows, net debt level and market conditions. During the three- and six-month periods ended June 30, 2014, the company repurchased 2.7 million shares and 6.4 million shares for $200 million and $450 million, respectively, under the board of directors’ July 2012 $2.0 billion share repurchase authorization. As of June 30, 2014, $571 million remained available under the July 2012 authorization.

Retirement_and_Other_Benefit_P

Retirement and Other Benefit Programs	6 Months Ended
	Jun. 30, 2014
Retirement and Other Benefit Programs	'
	9. RETIREMENT AND OTHER BENEFIT PROGRAMS
	The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Pension benefits
	Service cost		$33			$33			$  66			$  67
	Interest cost		60			51			120			102
	Expected return on plan assets		(68	)		(63	)		(134	)		(127	)
	Amortization of net losses and other deferred amounts		36			61			72			123
	Net periodic pension benefit cost		$61			$82			$124			$165
	OPEB
	Service cost		$  2			$  3			$    3			$    5
	Interest cost		7			6			14			13
	Amortization of net loss and prior service credit		—			2			—			4
	Net periodic OPEB cost		$  9			$11			$  17			$  22

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income	'
	10. ACCUMULATED OTHER COMPREHENSIVE INCOME
	Comprehensive income includes all changes in shareholders’ equity that do not arise from transactions with shareholders, and consists of net income, currency translation adjustments (CTA), pension and other employee benefits, unrealized gains and losses on cash flow hedges and unrealized gains and losses on unrestricted available-for-sale marketable equity securities. The following is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2014 and 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2013			$   (991	)		$(1,027	)		$10			$32			$(1,976	)
	Other comprehensive income before reclassifications			(207	)		2			(5	)		(7	)		(217	)
	Amounts reclassified from AOCI (a)			—			49			(1	)		—			48
	Net other comprehensive (loss) income			(207	)		51			(6	)		(7	)		(169	)
	Balance as of June 30, 2014			$(1,198	)		$   (976	)		$  4			$25			$(2,145	)
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012			$(1,227	)		$(1,619	)		$ (5	)		$41			$(2,810	)
	Other comprehensive income before reclassifications			(54	)		(6	)		41			(1	)		(20	)
	Amounts reclassified from AOCI (a)			—			83			(18	)		—			65
	Net other comprehensive (loss) income			(54	)		77			23			(1	)		45
	Balance as of June 30, 2013			$(1,281	)		$(1,542	)		$18			$40			$(2,765	)
	(a)	See table below for details about these reclassifications.
	The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2014 and 2013.
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Six months ended			Location of impact in income statement
			30-Jun-14			30-Jun-14
	Amortization of pension and other employee benefits items
	Actuarial losses and other			$(36	)(b)		$(72	)(b)
				(36	)		(72	)	Total before tax
				13			23		Tax benefit
				$(23	)		$(49	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ —			$  (1	)	Net interest expense
	Foreign exchange contracts			1			1		Net sales
	Foreign exchange contracts			(3	)		2		Cost of sales
				(2	)		2		Total before tax
				1			(1	)	Tax expense
				$  (1	)		$   1		Net of tax
	Total reclassification for the period			$(24	)		$(48	)	Total net of tax
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Six months ended			Location of impact in income statement
			30-Jun-13			30-Jun-13
	Amortization of pension and other employee benefits items
	Actuarial losses and other			$(63	)(b)		$(127	)(b)
				(63	)		(127	)	Total before tax
				22			44		Tax benefit
				$(41	)		$  (83	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ 11			$   11		Net interest expense
	Foreign exchange contracts			(1	)		(1	)	Net sales
	Foreign exchange contracts			16			18		Cost of sales
				26			28		Total before tax
				(9	)		(10	)	Tax expense
				$ 17			$   18		Net of tax
	Total reclassification for the period			$(24	)		$  (65	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.
	Refer to Note 9 for additional information regarding the amortization of pension and other employee benefits items and Note 7 for additional information regarding hedging activity.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
	11. INCOME TAXES
	Effective tax rate
	The company’s effective income tax rate was 21.3% and 20.6% in the three months ended June 30, 2014 and 2013, respectively, and 21.5% and 20.5% in the six months ended June 30, 2014 and 2013, respectively. The company’s effective income tax rate differs from the United States federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the United States federal statutory rate. In addition, the effective tax rate can be impacted each period by discrete factors and events.
	The effective income tax rate increased during the three and six months ended June 30, 2014 compared to the prior periods primarily as a result of certain discrete factors that favorably impacted the effective tax rate in the three and six months ended June 30, 2013. These 2013 items included realization of state tax credits and a net reduction in miscellaneous tax contingent matters.

Legal_Proceedings

Legal Proceedings	6 Months Ended
	Jun. 30, 2014
Legal Proceedings	'
	12. LEGAL PROCEEDINGS
	Baxter is involved in product liability, patent, commercial, and other legal matters that arise in the normal course of the company’s business. The company records a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, and no amount within the range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. As of June 30, 2014, the company’s total recorded reserves with respect to legal matters were $77 million and the total related receivables were $6 million.
	Baxter has established reserves for certain of the matters discussed below. The company is not able to estimate the amount or range of any loss for certain contingencies for which there is no reserve or additional loss for matters already reserved. While the liability of the company in connection with the claims cannot be estimated with any certainty and although the resolution in any reporting period of one or more of these matters could have a significant impact on the company’s results of operations and cash flows for that period, the outcome of these legal proceedings is not expected to have a material adverse effect on the company’s consolidated financial position. While the company believes that it has valid defenses in these matters, litigation is inherently uncertain, excessive verdicts do occur, and the company may incur material judgments or enter into material settlements of claims.
	In addition to the matters described below, the company remains subject to the risk of future administrative and legal actions. With respect to governmental and regulatory matters, these actions may lead to product recalls, injunctions, and other restrictions on the company’s operations and monetary sanctions, including significant civil or criminal penalties. With respect to intellectual property, the company may become exposed to significant litigation concerning the scope of the company’s and others’ rights. Such litigation could result in a loss of patent protection or the ability to market products, which could lead to a significant loss of sales, or otherwise materially affect future results of operations.
	General litigation
	Baxter is a defendant in a number of suits alleging that certain of the company’s current and former executive officers and its board of directors failed to adequately oversee the operations of the company and issued materially false and misleading statements regarding the company’s plasma-based therapies business, the company’s remediation of its COLLEAGUE infusion pumps, its heparin product, and other quality issues. Plaintiffs allege these actions damaged the company and its shareholders by resulting in a decline in stock price in the second quarter of 2010, payment of excess compensation to the board of directors and certain of the company’s current and former executive officers, and other damage to the company. In January 2014, an independent special litigation committee was established by the company’s board of directors to determine whether it is in the best interests of the company and its shareholders to pursue or otherwise resolve the claims raised in and arising from this matter. The company and the plaintiffs in the consolidated derivative suit filed in the U.S.D.C. for the Northern District of Illinois have entered into a revised memorandum of understanding outlining the terms of a settlement of that suit, including the establishment of a Regulatory Council for the Medical Products business, $12 million to be spent on quality and regulatory compliance initiatives over the next three years, and the payment of legal fees (which have been reserved). The settlement remains subject to the approval of the special litigation committee of the board of directors and the court. Two other derivative actions were previously filed in state courts, one in Lake County, Illinois and one in the Delaware Chancery Court, and both matters have been stayed pending the resolution of the federal action. In addition, a consolidated alleged class action is pending in the U.S.D.C. for the Northern District of Illinois against the company and certain of its current executive officers seeking to recover the lost value of investors’ stock and the parties are currently proceeding with discovery. In April 2013, the company filed its opposition to the plaintiff’s motion to certify a class action.
	The company was a defendant, along with others, in a number of lawsuits consolidated for pretrial proceedings in the U.S.D.C. for the Northern District of Illinois alleging that Baxter and certain of its competitors conspired to restrict output and artificially increase the price of plasma-derived therapies since 2003. Some of the complaints attempt to state a claim for class action relief and some cases demand treble damages. In January 2012, the court granted the company’s motion to dismiss certain federal claims brought by indirect purchasers and returned the remaining indirect purchaser claims to the court of original jurisdiction (U.S.D.C. for the Northern District of California) in August 2012. The indirect purchaser complaint was amended to remove class action allegations in May 2013. The company settled with the direct purchaser plaintiffs for $64 million, which was paid during the first quarter of 2014, and final court approval of the settlement was obtained in April 2014.
	Other
	In May 2014, the company received a formal demand for information from the United States Attorney for the Western District of Pennsylvania for information related to alleged “off-label” sales of its pulmonary treatments. The company is fully cooperating with this request.
	In the fourth quarter of 2012, the company received two investigative demands from the United States Attorney for the Western District of North Carolina for information regarding its quality and manufacturing practices and procedures at its North Cove facility. The company is fully cooperating with this investigation.

Segment_Information

Segment Information	6 Months Ended
	Jun. 30, 2014
Segment Information	'
	13. SEGMENT INFORMATION
	Baxter’s two segments, BioScience and Medical Products, are strategic businesses that are managed separately because each business develops, manufactures and markets distinct products and services. The segments and a description of their products and services are as follows:
	The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines.
	The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, Baxter has a comprehensive portfolio of renal therapies to meet the needs of patients across the treatment continuum. The portfolio includes innovative technologies and therapies for peritoneal dialysis, in-center hemodialysis, home hemodialysis, CRRT and additional dialysis services. The financial information for the three and six months ended June 30, 2014 includes the results of Gambro. As the acquisition was completed on September 6, 2013, the financial information for the three and six months ended June 30, 2013 does not include the results of Gambro.
	The company uses more than one measurement and multiple views of data to measure segment performance and to allocate resources to the segments. However, the dominant measurements are consistent with the company’s condensed consolidated financial statements and, accordingly, are reported on the same basis in this report. The company evaluates the performance of its segments and allocates resources to them primarily based on pre-tax income along with cash flows and overall economic returns. Intersegment sales are eliminated in consolidation.
	Certain items are maintained at Corporate and are not allocated to a segment. They primarily include most of the company’s debt and cash and equivalents and related net interest expense, certain foreign exchange fluctuations (principally relating to intercompany receivables, payables and loans denominated in a foreign currency) and the majority of the foreign currency hedging activities, corporate headquarters costs, stock compensation expense, certain non-strategic investments and related income and expense, certain employee benefit plan costs, certain nonrecurring gains and losses and other certain other charges (such as business optimization and asset impairment). With respect to depreciation and amortization and expenditures for long-lived assets, the difference between the segment totals and the consolidated totals principally relate to assets maintained at Corporate.
	Financial information for the company’s segments is as follows.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Net sales
	BioScience		$1,751			$1,638			$3,359			$3,168
	Medical Products		2,513			2,031			4,856			3,949
	Total net sales		$4,264			$3,669			$8,215			$7,117
	Pre-tax income
	BioScience		$   580			$   646			$1,177			$1,236
	Medical Products		258			373			551			695
	Total pre-tax income from segments		$   838			$1,019			$1,728			$1,931
	The following is a reconciliation of segment pre-tax income to income before income taxes per the condensed consolidated statements of income.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Total pre-tax income from segments		$838			$1,019			$1,728			$1,931
	Unallocated amounts
	Stock compensation		(41	)		(40	)		(72	)		(72	)
	Net interest expense		(42	)		(17	)		(85	)		(42	)
	Business optimization items		32			2			4			2
	Certain foreign currency fluctuations and hedging activities		10			25			26			42
	Other Corporate items		(136	)		(246	)		(231	)		(425	)
	Income before income taxes		$661			$   743			$1,370			$1,436

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	14. SUBSEQUENT EVENTS
	On July 29, 2014, the company entered into an agreement to sell the assets and liabilities associated with its vaccines for meningitis C and tick-borne encephalitis. As of June 30, 2014, the carrying amount of net assets to be disposed of was approximately $140 million, which primarily includes inventory and property, plant and equipment, net. The sale is expected to be completed in the second half of 2014.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
New accounting standards	'
	New accounting standards
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. ASU 2014-09 will be effective for the company beginning on January 1, 2017. Early adoption is not permitted. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The company is currently evaluating the impact of adopting the new revenue standard on its consolidated financial statements.

Supplemental_Financial_Informa1

Supplemental Financial Information (Tables)	6 Months Ended
	Jun. 30, 2014
Net Interest Expense	'
	Net interest expense
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Interest expense, net of capitalized interest		$47			$24			$95			$55
	Interest income		(5	)		(7	)		(10	)		(13	)
	Net interest expense		$42			$17			$85			$42
Inventories	'
	Inventories
		June 30,			December 31,
	(in millions)	2014			2013
	Raw materials		$   829			$   920
	Work in process		1,221			1,136
	Finished goods		1,786			1,443
	Inventories		$3,836			$3,499
Property, Plant and Equipment, Net	'
	Property, plant and equipment, net
		June 30,			December 31,
	(in millions)	2014			2013
	Property, plant and equipment, at cost		$14,366			$13,795
	Accumulated depreciation		(6,214	)		(5,963	)
	Property, plant and equipment (PP&E), net		$  8,152			$  7,832

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Reconciliation of Basic Shares to Diluted Shares	'
	The following is a reconciliation of basic shares to diluted shares.
		Three months ended				Six months ended
		June 30,				June 30,
	(in millions)	2014		2013		2014		2013
	Basic shares		542		543		542		543
	Effect of dilutive securities		6		6		6		7
	Diluted shares		548		549		548		550

Acquisitions_and_Collaboration1

Acquisitions and Collaborations (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Fair Value of Consideration Transferred and Recognized Amounts of Assets Acquired and Liabilities Assumed	'
	The following table summarizes the fair value of consideration transferred and the recognized amounts of the assets acquired and liabilities assumed as of the acquisition date for the company’s significant acquisitions during the first half of 2014.
	(in millions)	Chatham		AesRx
	Consideration transferred
	Cash		$  70		$15
	Contingent payments		77		65
	Fair value of consideration transferred		$147		$80
	Assets acquired and liabilities assumed
	Other intangible assets – IPR&D		$  74		$78
	Total identifiable net assets		74		78
	Goodwill		73		2
	Total assets acquired and liabilities assumed		$147		$80

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill	'
	The following is a reconciliation of goodwill by business segment.
	(in millions)	BioScience			Medical Products			Total
	Balance as of December 31, 2013		$   991			$3,214			$4,205
	Additions		75			4			79
	Currency translation and other adjustments		(4	)		(54	)		(58	)
	Balance as of June 30, 2014		$1,062			$3,164			$4,226
Other Intangible Assets, Net	'
	The following is a summary of the company’s other intangible assets.
	(in millions)	Developed technology,			Other amortized			Indefinite-lived			Total
		including patents			intangible assets			intangible assets
	June 30, 2014
	Gross other intangible assets		$2,123			$461			$612			$3,196
	Accumulated amortization		(731	)		(136	)		—			(867	)
	Other intangible assets, net		$1,392			$325			$612			$2,329
	December 31, 2013
	Gross other intangible assets		$2,144			$494			$465			$3,103
	Accumulated amortization		(665	)		(144	)		—			(809	)
	Other intangible assets, net		$1,479			$350			$465			$2,294

Infusion_Pump_and_Business_Opt1

Infusion Pump and Business Optimization Charges (Tables)	6 Months Ended
	Jun. 30, 2014
Business Optimization Charge	'
	The following table summarizes cash activity in the reserves related to the company’s business optimization initiatives.
	(in millions)
	Reserves as of December 31, 2013	$	288
	Charges		32
	Reserve adjustments		(35	)
	Utilization		(70	)
	Reserves as of June 30, 2014	$	215

Debt_Financial_Instruments_and1

Debt, Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Activity Relating to Securitization Arrangement	'
	The following is a summary of the activity relating to the company’s securitization arrangement in Japan.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Sold receivables at beginning of period		$109			$120			$114			$157
	Proceeds from sales of receivables		117			131			240			255
	Cash collections (remitted to the owners of the receivables)		(120	)		(123	)		(249	)		(264	)
	Effect of currency exchange rate changes		—			1			1			(19	)
	Sold receivables at end of period		$106			$129			$106			$129
Summary of Gains and Losses on Derivative Instruments	'
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the three months ended June 30, 2014 and 2013.
		Gain (loss) recognized in OCI						Location of gain (loss)			Gain (loss) reclassified from AOCI
								in income statement			into income
	(in millions)	2014			2013						2014			2013
	Cash flow hedges
	Interest rate contracts		$—			$21			Net interest expense			$—			$11
	Foreign exchange contracts		1			1			Net sales			1			(1	)
	Foreign exchange contracts		5			(17	)		Cost of sales			(3	)		16
	Total		$  6			$  5						$ (2	)		$26
					Gain (loss) recognized in income
	(in millions)	Location of gain (loss) in income statement			2014			2013
	Fair value hedges
	Interest rate contracts		Net interest expense			$ 17			$(21	)
	Undesignated derivative instruments
	Foreign exchange contracts		Other expense (income), net			$(22	)		$(44	)
	The following table summarizes the income statement locations and gains and losses on the company’s derivative instruments for the six months ended June 30, 2014 and 2013.
		Gain (loss) recognized in OCI						Location of gain (loss)			Gain (loss) reclassified from AOCI
								in income statement			into income
	(in millions)	2014			2013						2014			2013
	Cash flow hedges
	Interest rate contracts		$—			$26			Net interest expense			$(1	)		$11
	Foreign exchange contracts		—			—			Net sales			1			(1	)
	Foreign exchange contracts		(6	)		36			Cost of sales			2			18
	Total		$ (6	)		$62						$ 2			$28
					Gain (loss) recognized in income
	(in millions)	Location of gain (loss) in income statement			2014			2013
	Fair value hedges
	Interest rate contracts		Net interest expense			$ 31			$(26	)
	Undesignated derivative instruments
	Foreign exchange contracts		Other expense (income), net			$(10	)		$(45	)
Classification and Fair Value Amounts of Derivative Instruments	'
	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of June 30, 2014.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location			Fair value			Balance sheet location			Fair value
	Derivative instruments designated as hedges
	Interest rate contracts		Other long-term assets			$52
	Foreign exchange contracts		Prepaid expenses and other			19
	Foreign exchange contracts		Other long-term assets			2			Accounts payable			4
									and accrued liabilities
	Total derivative instruments designated as hedges					$73						$4
	Undesignated derivative instruments
	Foreign exchange contracts		Prepaid expenses and other			$—			Accounts payable			$1
									and accrued liabilities
	Total derivative instruments					$73						$5
	The following table summarizes the classification and fair values of derivative instruments reported in the condensed consolidated balance sheet as of December 31, 2013.
		Derivatives in asset positions						Derivatives in liability positions
	(in millions)	Balance sheet location			Fair value			Balance sheet location			Fair value
	Derivative instruments designated as hedges
	Interest rate contracts		Other long-term assets			$35			Other long-term liabilities			$14
	Foreign exchange contracts		Prepaid expenses and other			37			Accounts payable			7
									and accrued liabilities
	Total derivative instruments designated as hedges					$72						$21
	Undesignated derivative instruments
	Foreign exchange contracts		Prepaid expenses and other			$—			Accounts payable			$  1
									and accrued liabilities
	Total derivative instruments					$72						$22
Derivative Positions Presented on Net Basis	'
	The following table provides information on the company’s derivative positions as if they were presented on a net basis, allowing for the right of offset by counterparty:
		June 30, 2014						December 31, 2013
	(in millions)	Asset			Liability			Asset			Liability
	Gross amounts recognized in the consolidated balance sheet		$ 73			$   5			$ 72			$ 22
	Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet		(5	)		(5	)		(17	)		(17	)
	Total		$ 68			$  —			$ 55			$   5
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The following tables summarize the bases used to measure financial assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheets.
					Basis of fair value measurement
	(in millions)	Balance as of			Quoted prices in			Significant other			Significant
		June 30, 2014			active markets for			observable inputs			unobservable
					identical assets			(Level 2)			inputs
					(Level 1)						(Level 3)
	Assets
	Foreign currency hedges		$  21			$  —			$21			$  —
	Interest rate hedges		52			—			52			—
	Available-for-sale securities
	Equity securities		100			100			—			—
	Foreign government debt securities		18			—			18			—
	Total assets		$191			$100			$91			$  —
	Liabilities
	Foreign currency hedges		$    5			$  —			$  5			$  —
	Contingent payments related to acquisitions		523			—			—			523
	Total liabilities		$528			$  —			$  5			$523
					Basis of fair value measurement
	(in millions)	Balance as of			Quoted prices in			Significant other			Significant
		December 31, 2013			active markets for			observable inputs			unobservable
					identical assets			(Level 2)			inputs
					(Level 1)						(Level 3)
	Assets
	Foreign currency hedges		$  37			$  —			$37			$  —
	Interest rate hedges		35			—			35			—
	Available-for-sale securities
	Equity securities		102			102			—			—
	Foreign government debt securities		18			—			18			—
	Total assets		$192			$102			$90			$  —
	Liabilities
	Foreign currency hedges		$    8			$  —			$  8			$  —
	Interest rate hedges		14			—			14			—
	Contingent payments related to acquisitions and investments		340			—			—			340
	Total liabilities		$362			$  —			$22			$340
Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs	'
	The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consists of contingent payments related to acquisitions.
	(in millions)	Contingent
		payments
	Fair value as of December 31, 2013		$340
	Additions		142
	Net losses recognized in earnings		43
	CTA		(2	)
	Fair value as of June 30, 2014		$523
Book Values and Fair Values of Financial Instruments	'
	For these financial instruments, the following table provides the values recognized on the condensed consolidated balance sheets and the approximate fair values as of June 30, 2014 and December 31, 2013.
		Book values						Approximate fair values
	(in millions)	2014			2013			2014			2013
	Assets
	Long-term insurance receivables	$	2		$	2		$	2		$	2
	Investments		63			53			64			53
	Liabilities
	Short-term debt		186			181			186			181
	Current maturities of long-term debt and lease obligations		1,125			859			1,143			862
	Long-term debt and lease obligations		7,528			8,126			7,869			8,298
	Long-term litigation liabilities		55			72			54			70
Summarization of Bases Used to Measure Fair Value of Financial Instruments	'
	The following tables summarize the bases used to measure the approximate fair value of the financial instruments as of June 30, 2014 and December 31, 2013.
					Basis of fair value measurement
	(in millions)	Fair value as of			Quoted prices in			Significant other			Significant
		30-Jun-14			active markets for			observable inputs			unobservable
					identical assets			(Level 2)			inputs
					(Level 1)						(Level 3)
	Assets
	Long-term insurance receivables		$       2			$—			$     —			$  2
	Investments		64			—			19			45
	Total assets		$     66			$—			$     19			$47
	Liabilities
	Short-term debt		$   186			$—			$   186			$—
	Current maturities of long-term debt and lease obligations		1,143			—			1,143			—
	Long-term debt and lease obligations		7,869			—			7,869			—
	Long-term litigation liabilities		54			—			—			54
	Total liabilities		$9,252			$—			$9,198			$54
					Basis of fair value measurement
	(in millions)	Fair value as of			Quoted prices in			Significant other			Significant
		December 31, 2013			active markets for			observable inputs			unobservable
					identical assets			(Level 2)			inputs
					(Level 1)						(Level 3)
	Assets
	Long-term insurance receivables		$       2			$—			$     —			$  2
	Investments		53			—			17			36
	Total assets		$     55			$—			$     17			$38
	Liabilities
	Short-term debt		$   181			$—			$   181			$—
	Current maturities of long-term debt and lease obligations		862			—			862			—
	Long-term debt and lease obligations		8,298			—			8,298			—
	Long-term litigation liabilities		70			—			—			70
	Total liabilities		$9,411			$—			$9,341			$70

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2014
Stock Options Fair Value Assumptions	'
	The weighted-average assumptions used in estimating the fair value of stock options granted during the period, along with the weighted-average grant-date fair values, were as follows.
		Six months ended
		June 30,
		2014		2013
	Expected volatility		24%		25%
	Expected life (in years)		5.5		5.5
	Risk-free interest rate		1.70%		0.90%
	Dividend yield		2.80%		2.60%
	Fair value per stock option		$12		$12
Performance Stock Units Fair Value	'
	The assumptions used in estimating the fair value of these PSUs granted during the period, along with the grant-date fair values, were as follows.
		Six months ended
		June 30,
		2014		2013
	Baxter volatility		20%		21%
	Peer group volatility		13% – 58%		13% – 38%
	Correlation of returns		0.23 – 0.66		0.37 – 0.62
	Risk-free interest rate		0.70%		0.30%
	Fair value per PSU		$57		$67

Retirement_and_Other_Benefit_P1

Retirement and Other Benefit Programs (Tables)	6 Months Ended
	Jun. 30, 2014
Net Periodic Benefit Cost Relating to Pension and Other Postemployement Benefit	'
	The following is a summary of net periodic benefit cost relating to the company’s pension and other postemployment benefit (OPEB) plans.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Pension benefits
	Service cost		$33			$33			$  66			$  67
	Interest cost		60			51			120			102
	Expected return on plan assets		(68	)		(63	)		(134	)		(127	)
	Amortization of net losses and other deferred amounts		36			61			72			123
	Net periodic pension benefit cost		$61			$82			$124			$165
	OPEB
	Service cost		$  2			$  3			$    3			$    5
	Interest cost		7			6			14			13
	Amortization of net loss and prior service credit		—			2			—			4
	Net periodic OPEB cost		$  9			$11			$  17			$  22

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Changes in AOCI by Component	'
	The following is a net-of-tax summary of the changes in AOCI by component for the six months ended June 30, 2014 and 2013.
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2013			$   (991	)		$(1,027	)		$10			$32			$(1,976	)
	Other comprehensive income before reclassifications			(207	)		2			(5	)		(7	)		(217	)
	Amounts reclassified from AOCI (a)			—			49			(1	)		—			48
	Net other comprehensive (loss) income			(207	)		51			(6	)		(7	)		(169	)
	Balance as of June 30, 2014			$(1,198	)		$   (976	)		$  4			$25			$(2,145	)
	(in millions)		Currency			Pension and			Hedging			Other			Total
			translation			other employee			activities
			adjustments			benefits
	Gains (losses)
	Balance as of December 31, 2012			$(1,227	)		$(1,619	)		$ (5	)		$41			$(2,810	)
	Other comprehensive income before reclassifications			(54	)		(6	)		41			(1	)		(20	)
	Amounts reclassified from AOCI (a)			—			83			(18	)		—			65
	Net other comprehensive (loss) income			(54	)		77			23			(1	)		45
	Balance as of June 30, 2013			$(1,281	)		$(1,542	)		$18			$40			$(2,765	)
	(a)	See table below for details about these reclassifications.
Summary of Reclassification from AOCI to Net Income	'
	The following is a summary of the amounts reclassified from AOCI to net income during the three and six months ended June 30, 2014 and 2013.
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Six months ended			Location of impact in income statement
			30-Jun-14			30-Jun-14
	Amortization of pension and other employee benefits items
	Actuarial losses and other			$(36	)(b)		$(72	)(b)
				(36	)		(72	)	Total before tax
				13			23		Tax benefit
				$(23	)		$(49	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ —			$  (1	)	Net interest expense
	Foreign exchange contracts			1			1		Net sales
	Foreign exchange contracts			(3	)		2		Cost of sales
				(2	)		2		Total before tax
				1			(1	)	Tax expense
				$  (1	)		$   1		Net of tax
	Total reclassification for the period			$(24	)		$(48	)	Total net of tax
			Amounts reclassified from AOCI (a)
	(in millions)		Three months ended			Six months ended			Location of impact in income statement
			30-Jun-13			30-Jun-13
	Amortization of pension and other employee benefits items
	Actuarial losses and other			$(63	)(b)		$(127	)(b)
				(63	)		(127	)	Total before tax
				22			44		Tax benefit
				$(41	)		$  (83	)	Net of tax
	Gains (losses) on hedging activities
	Interest rate contracts			$ 11			$   11		Net interest expense
	Foreign exchange contracts			(1	)		(1	)	Net sales
	Foreign exchange contracts			16			18		Cost of sales
				26			28		Total before tax
				(9	)		(10	)	Tax expense
				$ 17			$   18		Net of tax
	Total reclassification for the period			$(24	)		$  (65	)	Total net of tax
	(a)	Amounts in parentheses indicate reductions to net income.
	(b)	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.

Segment_Information_Tables

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Information	'
	Financial information for the company’s segments is as follows.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Net sales
	BioScience		$1,751			$1,638			$3,359			$3,168
	Medical Products		2,513			2,031			4,856			3,949
	Total net sales		$4,264			$3,669			$8,215			$7,117
	Pre-tax income
	BioScience		$   580			$   646			$1,177			$1,236
	Medical Products		258			373			551			695
	Total pre-tax income from segments		$   838			$1,019			$1,728			$1,931
Pre-Tax Income Reconciliation	'
	The following is a reconciliation of segment pre-tax income to income before income taxes per the condensed consolidated statements of income.
		Three months ended						Six months ended
		June 30,						June 30,
	(in millions)	2014			2013			2014			2013
	Total pre-tax income from segments		$838			$1,019			$1,728			$1,931
	Unallocated amounts
	Stock compensation		(41	)		(40	)		(72	)		(72	)
	Net interest expense		(42	)		(17	)		(85	)		(42	)
	Business optimization items		32			2			4			2
	Certain foreign currency fluctuations and hedging activities		10			25			26			42
	Other Corporate items		(136	)		(246	)		(231	)		(425	)
	Income before income taxes		$661			$   743			$1,370			$1,436

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Basis of Presentation [Line Items]	'
Business separation cost	$22

Net_Interest_Expense_Detail

Net Interest Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Interest Income Expense Net	'	'	'	'
Interest expense, net of capitalized interest	$47	$24	$95	$55
Interest income	-5	-7	-10	-13
Net interest expense	$42	$17	$85	$42

Inventories_Detail

Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory	'	'
Raw materials	$829	$920
Work in process	1,221	1,136
Finished goods	1,786	1,443
Inventories	$3,836	$3,499

Property_Plant_and_Equipment_N

Property, Plant and Equipment ,Net (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Property, Plant and Equipment, Net	'	'
Property, plant and equipment, at cost	$14,366	$13,795
Accumulated depreciation	-6,214	-5,963
Property, plant and equipment (PP&E), net	$8,152	$7,832

Reconciliation_of_Basic_Shares

Reconciliation of Basic Shares to Diluted Shares (Detail)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Reconciliation of Basic Shares to Diluted Shares	'	'	'	'
Basic shares	542	543	542	543
Effect of dilutive securities	6	6	6	7
Diluted shares	548	549	548	550

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Reconciliation of Basic Shares to Diluted Shares	'	'	'	'
Anti-dilutive securities excluded from computation of EPS	11	6	9	6

Summary_of_Fair_Value_of_Consi

Summary of Fair Value of Consideration Transferred and Recognized Amounts of Assets Acquired and Liabilities Assumed (Detail) (USD $)	6 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Apr. 30, 2014	Jun. 30, 2014
				Chatham Therapeutics	AesRx LLC
Consideration transferred	'	'	'	'	'
Cash	$176	$87	'	$70	$15
Contingent payments	'	'	'	77	65
Fair value of consideration transferred	'	'	'	147	80
Assets acquired and liabilities assumed	'	'	'	'	'
Other intangible assets - IPR&D	'	'	'	74	78
Total identifiable net assets	'	'	'	74	78
Goodwill	4,226	'	4,205	73	2
Total assets acquired and liabilities assumed	'	'	'	$147	$80

Acquisitions_and_Collaboration2

Acquisitions and Collaborations - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Millions, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Sep. 06, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Apr. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Indap Holding AB

AesRx LLC

AesRx LLC

AesRx LLC

AesRx LLC

AesRx LLC

Chatham Therapeutics

Chatham Therapeutics

Chatham Therapeutics

Chatham Therapeutics

Chatham Therapeutics

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Gambro AB

Coherus Biosciences

Coherus Biosciences

Coherus Biosciences

Minimum

In-process research and development (IPR&D)

Development, regulatory and commercial milestones

Sales Milestone

Minimum

In-process research and development (IPR&D)

Development, regulatory and commercial milestones

Sales Milestone

Marketing and administrative

Marketing and administrative

Marketing and administrative

Marketing and administrative

Maximum

Maximum

Maximum

Acquisitions And Collaborations [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial payment under the agreement

'

'

'

'

'

'

$15

'

'

'

'

$70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business collaboration contingent consideration potential cash payment

'

'

'

'

'

'

'

'

'

278

550

'

'

'

560

780

'

'

'

'

'

'

'

'

'

94

Contingent payments related to acquisitions

'

'

'

'

'

'

65

'

'

'

'

77

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangible assets

'

'

'

'

'

'

78

'

78

'

'

74

'

74

'

'

'

'

'

'

'

'

'

'

'

'

Acquired IPR&D completion period

'

'

'

'

'

'

'5 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

4,226

'

4,226

'

4,205

'

2

'

'

'

'

73

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash flow projections discount rate

'

'

'

'

'

'

15.50%

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incremental research and development costs projected

'

'

'

'

'

'

'

40

'

'

'

'

130

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of voting interest acquired

'

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Measurement period adjustments, property, plant and equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

'

'

'

'

'

'

'

Measurement period adjustments, working capital adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

Measurement period adjustments, goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16

'

'

'

'

'

'

'

'

Change in consideration transferred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

Measurement period adjustments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

Integration charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

29

'

63

'

'

'

'

Business acquisition, pre acquisition

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23

'

40

'

'

'

Loss on divestiture of legacy Continuous Renal Replacement Therapy (CRRT) business

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

19

'

'

'

'

'

'

'

Research and development charges

$325

$273

$638

$519

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$35

$60

'

Goodwill_Detail

Goodwill (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Goodwill [Line Items]	'
Goodwill, beginning balance	$4,205
Additions	79
Currency translation and other adjustments	-58
Goodwill, ending balance	4,226
BioScience	'
Goodwill [Line Items]	'
Goodwill, beginning balance	991
Additions	75
Currency translation and other adjustments	-4
Goodwill, ending balance	1,062
Medical Products	'
Goodwill [Line Items]	'
Goodwill, beginning balance	3,214
Additions	4
Currency translation and other adjustments	-54
Goodwill, ending balance	$3,164

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Goodwill And Other Intangible Asset [Line Items]	'	'	'	'
Accumulated goodwill impairment losses	$0	'	$0	'
Amortization expense	47	25	90	50
Anticipated annual amortization expense of other intangible assets for 2014	182	'	182	'
Anticipated annual amortization expense of other intangible assets for 2015	183	'	183	'
Anticipated annual amortization expense of other intangible assets for 2016	179	'	179	'
Anticipated annual amortization expense of other intangible assets for 2017	161	'	161	'
Anticipated annual amortization expense of other intangible assets for 2018	157	'	157	'
Anticipated annual amortization expense of other intangible assets for 2019	$143	'	$143	'

Other_Intangible_Assets_Net_De

Other Intangible Assets, Net (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	$3,196	$3,103
Accumulated amortization	-867	-809
Other intangible assets, net	2,329	2,294
Developed technology, including patents	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	2,123	2,144
Accumulated amortization	-731	-665
Other intangible assets, net	1,392	1,479
Other Intangible Assets	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	461	494
Accumulated amortization	-136	-144
Other intangible assets, net	325	350
Indefinite Lived Intangible Assets	'	'
Intangible Asset Excluding Goodwill [Line Items]	'	'
Gross other intangible assets	612	465
Accumulated amortization	0	'
Other intangible assets, net	$612	$465

Infusion_Pump_and_Business_Opt2

Infusion Pump and Business Optimization Charges - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended	60 Months Ended	108 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2013
Infusion Pump Charges	'	'	'	'
Infusion pump and other product-related charges	'	$93	'	$888
Infusion pump charges related to cash	'	'	'	725
Infusion pump charges related asset impairments	'	'	'	163
Infusion pump utilization	'	13	'	'
Infusion pump cash reserves	70	70	83	83
Business Optimization Charges	'	'	'	'
Costs associated with optimizing the cost structure	'	'	992	'
Business optimization reserve, net benefit	32	'	'	'
Cash	'	'	'	'
Business Optimization Charges	'	'	'	'
Costs associated with optimizing the cost structure	'	-32	689	'
Cash reserves	215	215	288	288
Business optimization reserve, total adjustments	'	-35	'	'
Non Cash	'	'	'	'
Business Optimization Charges	'	'	'	'
Costs associated with optimizing the cost structure	'	'	303	'
Previous Business Optimization	'	'	'	'
Business Optimization Charges	'	'	'	'
Business optimization reserve, total adjustments	'	37	'	'
Severance and employee-related costs	'	'	'	'
Business Optimization Charges	'	'	'	'
Costs associated with optimizing the cost structure	'	$33	'	'

Business_Optimization_Charges_

Business Optimization Charges (Detail) (USD $)	6 Months Ended	60 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Business Optimization Initiatives	'	'
Charges	'	($992)
Cash	'	'
Business Optimization Initiatives	'	'
Reserve, beginning balance	288	'
Charges	32	-689
Reserve adjustments	-35	'
Utilization	-70	'
Reserve, ending balance	$215	$288

Summary_of_Activity_Relating_t

Summary of Activity Relating to Securitization Arrangement (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accounts Receivable Securitization [Line Items]	'	'	'	'
Sold receivables at beginning of period	$109	$120	$114	$157
Proceeds from sales of receivables	117	131	240	255
Cash collections (remitted to the owners of the receivables)	-120	-123	-249	-264
Effect of currency exchange rate changes	'	1	1	-19
Sold receivables at end of period	$106	$129	$106	$129

Debt_Financial_Instruments_and2

Debt, Financial Instruments and Fair Value Measurements - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Apr. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2013

Mar. 31, 2013

Countries With Liquidity Issues

Countries With Liquidity Issues

Fair Value, Inputs, Level 2

Equity Securities

Equity Securities

Other Income Loss Net

Gambro AB

Gambro AB

Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc.

Chatham Therapeutics

AesRx LLC

Commercial Paper

Fair value hedges

Fair value hedges

Domestic Line of Credit

Domestic Line of Credit

Foreign Line of Credit

Foreign Line of Credit

Foreign exchange contract

Foreign exchange contract

Interest rate contract

Interest rate contract

Interest rate contract

Terminated Fair Value Hedge

Terminated Fair Value Hedge

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Total notional amount of undesignated derivative instruments

Greece

Gambro AB

Gambro AB

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility Amount Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

$0

$124,000,000

'

'

'

'

'

'

'

'

'

'

'

Commercial paper outstanding

150,000,000

'

150,000,000

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument, weighted average interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.17%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total accounts receivable from certain countries with liquidity issues

'

'

'

'

'

'

450,000,000

37,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative notional amount

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,700,000,000

1,200,000,000

'

'

'

'

1,600,000,000

2,100,000,000

0

0

1,000,000,000

0

0

397,000,000

381,000,000

1,500,000,000

3,700,000,000

Maximum length of time hedge in cash flow hedge

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on Cash Flow Hedge

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on Interest rate contracts designated as cash flow hedge

'

11,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining deferred net loss to be amortized to net interest expense

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contract maturity period

'

'

'

'

'

'

'

'

'

'

'

'

'2013-06

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative losses

'

'

'

'

'

'

'

'

'

'

'

'

55,000,000

72,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gains (losses) on hedged item in fair value hedge

-17,000,000

21,000,000

-31,000,000

26,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred, net after-tax losses on derivative instruments

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and equivalents

1,866,000,000

5,989,000,000

1,866,000,000

5,989,000,000

2,733,000,000

3,270,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Money market funds, at carrying value

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average probability

'

'

27.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities amortized cost basis

118,000,000

'

118,000,000

'

111,000,000

'

'

'

'

'

'

'

'

'

59,000,000

60,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities fair value

100,000,000

'

100,000,000

'

102,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities net unrealized gain (loss)

'

'

'

'

'

'

'

'

'

-18,000,000

-9,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities cumulative unrealized losses

-47,000,000

'

-47,000,000

'

-31,000,000

'

'

'

'

'

'

'

'

'

-45,000,000

-30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Available for sale equity securities cumulative unrealized gain

29,000,000

'

29,000,000

'

22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent payments related to acquisitions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

77,000,000

65,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain recognized from sale of equity method investment

'

'

'

'

'

'

'

'

'

'

'

$44,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Gains_and_Losses_on

Summary of Gains and Losses on Derivative Instruments (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Net interest expense	($42)	($17)	($85)	($42)
Net sales	4,264	3,669	8,215	7,117
Cost of sales	-2,223	-1,730	-4,213	-3,422
Net income	520	590	1,076	1,142
Not Designated as Hedging Instrument | Other (income) expense, net	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in income, undesignated derivative instruments	-22	-44	-10	-45
Cash Flow Hedges	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in OCI	6	5	-6	62
Cash Flow Hedges | Interest rate contract	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in OCI	'	21	'	26
Cash Flow Hedges | Foreign Exchange Contracts One	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in OCI	1	1	'	'
Cash Flow Hedges | Foreign Exchange Contracts Two	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in OCI	5	-17	-6	36
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Net income	-2	26	2	28
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Interest rate contract | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Net interest expense	'	11	-1	11
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Foreign Exchange Contracts One | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Net sales	1	-1	1	-1
Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income | Foreign Exchange Contracts Two | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Cost of sales	-3	16	2	18
Fair value hedges | Interest Expense	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Gain (loss) recognized in income, fair value hedges	$17	($21)	$31	($26)

Classification_and_Fair_Value_

Classification and Fair Value Amounts of Derivative Instruments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	$73	$72
Derivative liability, fair value	5	22
Designated as Hedging Instrument	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	73	72
Derivative liability, fair value	4	21
Designated as Hedging Instrument | Interest rate contract | Other Long Term Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	'	14
Designated as Hedging Instrument | Interest rate contract | Other Long -Term Assets	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	52	35
Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	4	7
Designated as Hedging Instrument | Foreign exchange contract | Other Long -Term Assets	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	2	'
Designated as Hedging Instrument | Foreign exchange contract | Prepaid Expense And Other	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative asset, fair value	19	37
Not Designated as Hedging Instrument | Foreign exchange contract | Accounts Payable And Accrued Liabilities	'	'
Derivatives, Fair Value [Line Items]	'	'
Derivative liability, fair value	$1	$1

Derivative_Positions_Presented

Derivative Positions Presented On Net Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Gross amounts recognized in the consolidated balance sheet, asset	$73	$72
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset	-5	-17
Total	68	55
Gross amounts recognized in the consolidated balance sheet, liability	5	22
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability	-5	-17
Total	$0	$5

Financial_Assets_and_Liabiliti

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Equity securities	$100	$102
Fair Value, Measurements, Recurring	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedges, assets at fair value	21	37
Interest rate hedges, assets at fair value	52	35
Equity securities	100	102
Total assets	191	192
Foreign currency hedges, liabilities at fair value	5	8
Interest rate hedges, liabilities at fair value	'	14
Contingent payments related to acquisitions	523	340
Total liabilities	528	362
Fair Value, Measurements, Recurring | Foreign Government Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Debt securities	18	18
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Equity securities	100	102
Total assets	100	102
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedges, assets at fair value	21	37
Interest rate hedges, assets at fair value	52	35
Total assets	91	90
Foreign currency hedges, liabilities at fair value	5	8
Interest rate hedges, liabilities at fair value	'	14
Total liabilities	5	22
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | Foreign Government Debt Securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Debt securities	18	18
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Contingent payments related to acquisitions	523	340
Total liabilities	$523	$340

Reconciliation_of_Fair_Value_M

Reconciliation of Fair Value Measurements that Use Significant Unobservable Inputs (Detail) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Contingent payments, Fair value as of beginning of period	$340
Contingent payments, additions	142
Contingent payments, net losses recognized in earnings	43
Contingent payments,CTA	-2
Contingent payments, Fair value as of end of period	$523

Book_Values_and_Fair_Values_of

Book Values and Fair Values of Financial Instruments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'	'
Long-term debt and lease obligations	$7,528	$8,126
Book Values	'	'
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'	'
Long-term insurance receivables	2	2
Investments	63	53
Short-term debt	186	181
Current maturities of long-term debt and lease obligations	1,125	859
Long-term debt and lease obligations	7,528	8,126
Long-term litigation liabilities	55	72
Approximate fair values	'	'
Fair Value And Carrying Value By Balance Sheet Grouping [Line Items]	'	'
Long-term insurance receivables	2	2
Investments	64	53
Short-term debt	186	181
Current maturities of long-term debt and lease obligations	1,143	862
Long-term debt and lease obligations	7,869	8,298
Long-term litigation liabilities	$54	$70

Summarization_of_Bases_Used_to

Summarization of Bases Used to Measure Fair Value of Financial Instruments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long-term debt and lease obligations	$7,528	$8,126
Approximate fair values	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long-term insurance receivables	2	2
Investments	64	53
Total assets	66	55
Short-term debt	186	181
Current maturities of long-term debt and lease obligations	1,143	862
Long-term debt and lease obligations	7,869	8,298
Long-term litigation liabilities	54	70
Total liabilities	9,252	9,411
Fair Value, Inputs, Level 2 | Approximate fair values	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Investments	19	17
Total assets	19	17
Short-term debt	186	181
Current maturities of long-term debt and lease obligations	1,143	862
Long-term debt and lease obligations	7,869	8,298
Total liabilities	9,198	9,341
Fair Value, Inputs, Level 3 | Approximate fair values	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Long-term insurance receivables	2	2
Investments	45	36
Total assets	47	38
Long-term litigation liabilities	54	70
Total liabilities	$54	$70

Shareholders_Equity_Additional

Shareholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended			6 Months Ended
	Jul. 31, 2012	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Stock compensation expense	'	$41,000,000	'	$40,000,000	$72,000,000	$72,000,000
Stock based compensation in marketing and administrative expenses	'	70.00%	'	70.00%	70.00%	70.00%
Stock Options granted	'	'	6,500,000	'	'	'
Share repurchases	'	2,700,000	'	'	6,400,000	'
Value of share repurchases	'	200,000,000	'	'	450,000,000	'
Stock repurchase program, authorized amount	2,000,000,000	'	'	'	'	'
Remaining value available under stock repurchase programs	'	'	'	'	571,000,000	'
Minimum	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Common shares received as a percentage of performance shares	'	'	'	'	0.00%	'
Maximum	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Common shares received as a percentage of performance shares	'	'	'	'	200.00%	'
Senior Management | Performance Based Awards With Market Conditions	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Performance condition to percentage of market basis	'	'	'	'	50.00%	'
Restricted Stock Units	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Awards Granted	'	283,000	854,000	'	'	'
Unrecognized compensation cost related to all unvested	'	110,000,000	'	'	110,000,000	'
Weighted-average period for all unvested	'	'	'	'	'1 year 10 months 24 days	'
Performance Shares	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Awards Granted	'	'	335,000	'	'	'
Unrecognized compensation cost related to all unvested	'	22,000,000	'	'	22,000,000	'
Weighted-average period for all unvested	'	'	'	'	'1 year 4 months 24 days	'
Employee Stock Option	'	'	'	'	'	'
Stockholders Equity Note [Line Items]	'	'	'	'	'	'
Total intrinsic value of stock options exercised	'	34,000,000	'	46,000,000	79,000,000	107,000,000
Unrecognized compensation cost related to all unvested	'	$95,000,000	'	'	$95,000,000	'
Weighted-average period for all unvested	'	'	'	'	'1 year 10 months 24 days	'

Stock_Options_Fair_Value_Assum

Stock Options Fair Value Assumptions (Detail) (Employee Stock Option, USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Option	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected volatility	24.00%	25.00%
Expected life (in years)	'5 years 6 months	'5 years 6 months
Risk-free interest rate	1.70%	0.90%
Dividend yield	2.80%	2.60%
Fair value per stock option	$12	$12

Performance_Stock_Units_Fair_V

Performance Stock Units Fair Value Assumptions (Detail) (Performance Shares, USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Performance Shares	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Baxter volatility	20.00%	21.00%
Peer group volatility	'	'
Peer group volatility minimum	13.00%	13.00%
Peer group volatility maximum	58.00%	38.00%
Correlation of returns	'	'
Correlation of returns minimum	0.23	0.37
Correlation of returns maximum	0.66	0.62
Risk-free interest rate	0.70%	0.30%
Fair value per PSU	$57	$67

Net_Periodic_Benefit_Cost_Deta

Net Periodic Benefit Cost (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Pension Plans, Defined Benefit	'	'	'	'
Net periodic benefit cost	'	'	'	'
Service cost	$33	$33	$66	$67
Interest cost	60	51	120	102
Expected return on plan assets	-68	-63	-134	-127
Amortization of net loss and prior service credit/other deferred amounts	36	61	72	123
Net periodic benefit cost	61	82	124	165
Other Postretirement Benefit Plans, Defined Benefit	'	'	'	'
Net periodic benefit cost	'	'	'	'
Service cost	2	3	3	5
Interest cost	7	6	14	13
Amortization of net loss and prior service credit/other deferred amounts	'	2	'	4
Net periodic benefit cost	$9	$11	$17	$22

Summary_of_Changes_in_AOCI_by_

Summary of Changes in AOCI by Component (Detail) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'		'		'		'
Currency translation adjustment, Beginning Balance	'		'		($991)		($1,227)
Currency translation adjustment, other comprehensive income (loss) before reclassifications	'		'		-207		-54
Currency translation adjustment, amounts reclassified from AOCI	'		'		'	[1]	'	[1]
Currency translation adjustment, net other comprehensive (loss) income	-213		-30		-207		-54
Currency translation adjustment, Ending Balance	-1,198		-1,281		-1,198		-1,281
Pension and other employee benefit, Beginning Balance	'		'		-1,027		-1,619
Pension and other employee benefit, Other comprehensive income (loss) before reclassifications	'		'		2		-6
Pension and other employee benefit, Amounts reclassified from AOCI	23	[2]	41	[2]	49	[1],[2]	83	[1],[2]
Pension and other employee benefit, Net other comprehensive (loss) income	28		32		51		77
Pension and other employee benefit, Ending Balance	-976		-1,542		-976		-1,542
Hedging activities, Beginning Balance	'		'		10		-5
Hedging activities, Other comprehensive income (loss) before reclassifications	'		'		-5		41
Hedging activities, Amounts reclassified from AOCI	1	[2]	-17	[2]	-1	[1],[2]	-18	[1],[2]
Hedging activities, Net other comprehensive (loss) income	4		-13		-6		23
Hedging activities, Ending Balance	4		18		4		18
Other, Beginning Balance	'		'		32		41
Other, Other comprehensive income (loss) before reclassifications	'		'		-7		-1
Other, Amounts reclassified from AOCI	'		'		'	[1]	'	[1]
Other, Net other comprehensive (loss) income	-18		3		-7		-1
Other, Ending Balance	25		40		25		40
Total, Beginning Balance	'		'		-1,976		-2,810
Total, Other comprehensive income (loss) before reclassifications	'		'		-217		-20
Total, Amounts reclassified from AOCI	24	[2]	24	[2]	48	[1],[2]	65	[1],[2]
Total other comprehensive (loss) income, net of tax	-199		-8		-169		45
Total, Ending Balance	($2,145)		($2,765)		($2,145)		($2,765)
[1]	See table below for details about these reclassifications.
[2]	Amounts in parentheses indicate reductions to net income.

Summary_of_Amounts_Reclassific

Summary of Amounts Reclassification from AOCI to Net Income (Detail) (USD $)	3 Months Ended				6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($36)	[1]	($63)	[1]	($72)	[1]	($127)	[1]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, tax benefit	13	[1]	22	[1]	23	[1]	44	[1]
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, net of tax	-23	[1]	-41	[1]	-49	[1],[2]	-83	[1],[2]
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	-2	[1]	26	[1]	2	[1]	28	[1]
Gains (losses) on hedging activities reclassified from AOCI to net income, tax expense	1	[1]	-9	[1]	-1	[1]	-10	[1]
Gains (loss) on hedging activities reclassified from AOCI to net income, net of tax	-1	[1]	17	[1]	1	[1],[2]	18	[1],[2]
Total reclassification for the period	-24	[1]	-24	[1]	-48	[1],[2]	-65	[1],[2]
Interest rate contract | Interest Expense	'		'		'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	'		11	[1]	-1	[1]	11	[1]
Foreign exchange contract | Net Sales	'		'		'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	1	[1]	-1	[1]	1	[1]	-1	[1]
Foreign exchange contract | Cost of Sales	'		'		'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Gains (losses) on hedging activities reclassified from AOCI to net income, before tax	-3	[1]	16	[1]	2	[1]	18	[1]
Actuarial losses and other	'		'		'		'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]	'		'		'		'
Amortization of pension and other employee benefits items Actuarial losses and other reclassified from AOCI to net income, before tax	($36)	[1],[3]	($63)	[1],[3]	($72)	[1],[3]	($127)	[1],[3]
[1]	Amounts in parentheses indicate reductions to net income.
[2]	See table below for details about these reclassifications.
[3]	These AOCI components are included in the computation of net periodic benefit cost disclosed in Note 9.

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Taxes [Line Items]	'	'	'	'
Effective income tax rate	21.30%	20.60%	21.50%	20.50%

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Jun. 30, 2014	Jan. 31, 2014
Loss Contingencies [Line Items]	'	'	'
Total legal liabilities	'	$77	'
Litigation related receivables	'	6	'
Derivative action settlement amount	'	'	12
Settlement amount	$64	'	'
Other Litigation Cases	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of derivative actions filed in state court	2	'	'
Illinois State	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of derivative actions filed in state court	1	'	'
Delaware	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of derivative actions filed in state court	1	'	'

Segment_Information_Additional

Segment Information - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Segment
Segment Information [Line Items]	'
Number of segments	2

Segment_Information_Detail

Segment Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Information [Line Items]	'	'	'	'
Net sales	$4,264	$3,669	$8,215	$7,117
Pre-tax income	838	1,019	1,728	1,931
BioScience	'	'	'	'
Segment Information [Line Items]	'	'	'	'
Net sales	1,751	1,638	3,359	3,168
Pre-tax income	580	646	1,177	1,236
Medical Products	'	'	'	'
Segment Information [Line Items]	'	'	'	'
Net sales	2,513	2,031	4,856	3,949
Pre-tax income	$258	$373	$551	$695

Pre_Tax_Income_Reconciliation_

Pre- Tax Income Reconciliation (Detail) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	$661	$743	$1,370	$1,436
Operating Segments	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	838	1,019	1,728	1,931
Unallocated Amount To Segment Stock Compensation	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	-41	-40	-72	-72
Unallocated Amount To Segment Net Interest Expense	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	-42	-17	-85	-42
Unallocated Amount To Segment Business Optimization Items	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	32	2	4	2
Unallocated Amount To Segment Certain Foreign Currency Fluctuations and Hedging Activities	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	10	25	26	42
Unallocated Amount to Segment Other Corporate Items	'	'	'	'
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]	'	'	'	'
Income before income taxes	($136)	($246)	($231)	($425)

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Subsequent Event [Line Items]	'
Carrying amount of net assets to be disposed of	$140